| [1] | Juraschka K, Taylor MD. Medulloblastoma in the age of molecular subgroups: a review[J]. J Neurosurg Pediatr, 2019, 24(4): 353-363. doi: 10.3171/2019.5.PEDS18381
 | 
																													
																							| [2] | Louis DN, Perry A, Reifenberger G,  et al. The 2016 world health organization classification of tumors of the central nervers system: a summary[J]. Acta Neuropathol, 2016, 131(6): 803-820. doi: 10.1007/s00401-016-1545-1
 | 
																													
																							| [3] | Zou H, Poore B, Broniscer A,  et al. Molecular heterogeneity and cellular diversity: implications for precision treatment in medulloblastoma[J]. Cancers (Basel), 2020, 12(3): 643. doi: 10.3390/cancers12030643
 | 
																													
																							| [4] | Tamayo-Orrego L, Charron F. Recent advances in SHH medulloblastoma progression: tumor suppressor mechanisms and the tumor microenvironment[J]. F1000Res, 2019, 8: F1000 Faculty Rev-1823. | 
																													
																							| [5] | PDQ Pediatric Treatment Editorial Board. Childhood medulloblastoma and other central nervous system embryonal tumors treatment (PDQ): health professional version. bethesda (MD):  National Cancer Institute (US); 2002. | 
																													
																							| [6] | Thompson EM, Hielscher T, Bouffet E,  et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis[J]. Lancet Oncol, 2016, 17(4): 484-495. doi: S1470-2045(15)00581-1
																																					pmid: 26976201
 | 
																													
																							| [7] | Laurent JP, Chang CH, Cohen ME. A classification system for primitive neuroectodermal tumors (medulloblastoma) of the posterior fossa[J]. Cancer, 1985, 56(7 Suppl):1807-1809. pmid: 4027916
 | 
																													
																							| [8] | Northcott PA, Korshunov A, Witt H,  et al. Medulloblastoma comprises four distinct molecular variants[J]. J Clin Oncol, 2011, 29(11): 1408-1414. doi: 10.1200/JCO.2009.27.4324
																																					pmid: 20823417
 | 
																													
																							| [9] | Ramaswamy V, Remke M, Bouffet E,  et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus[J]. Acta Neuropathol, 2016, 131(6): 821-831. doi: 10.1007/s00401-016-1569-6
																																					pmid: 27040285
 | 
																													
																							| [10] | 杜淑旭, 李苗, 张金,  等. 儿童髓母细胞瘤的预后因素和生存分析[J]. 中华实用儿科临床杂志, 2019, 34 (24): 1886-1890. | 
																													
																							| [11] | Khatua S, Song A, Sridhar DC,  et al. Childhood medulloblastoma: current therapies, emerging molecular landscape and newer therapeutic insights[J]. Curr Neuropharmacol, 2018, 16(7): 1045-1058. doi: 10.2174/1570159X15666171129111324
																																					pmid: 29189165
 | 
																													
																							| [12] | Rolland A, Aquilina K. Surgery for recurrent-medul loblastoma: a review[J]. Neurochirurgie, 2021, 67(1): 69-75. doi: 10.1016/j.neuchi.2019.06.008
																																					pmid: 31351079
 | 
																													
																							| [13] | Packer RJ, Zhou T, Holmes E,  et al. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961[J]. Neuro Oncol, 2013, 15(1): 97-103. doi: 10.1093/neuonc/nos267
 | 
																													
																							| [14] | Huang PI, Lin SC, Lee YY,  et al. Large cell/anaplastic medulloblastoma is associated with poor prognosis—a retrospective analysis at a single institute[J]. Childs Nerv Syst, 2017, 33(8): 1285-1294. doi: 10.1007/s00381-017-3435-9
 | 
																													
																							| [15] | Cavalli FMG, Remke M, Rampasek L,  et al. Intertumoral heterogeneity within medulloblastoma subgroups[J]. Cancer Cell, 2017, 31(6): 737-754. doi: S1535-6108(17)30201-5
																																					pmid: 28609654
 | 
																													
																							| [16] | Rutkowski S, von Hoff K, Emser A,  et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis[J]. J Clin Oncol, 2010, 28(33): 4961-4968. doi: 10.1200/JCO.2010.30.2299
																																					pmid: 20940197
 | 
																													
																							| [17] | Gajjar A, Robinson GW, Smith KS,  et al. Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03)[J]. J Clin Oncol, 2021, 39(7): 822-835. doi: 10.1200/JCO.20.01372
																																					pmid: 33405951
 | 
																													
																							| [18] | Menyhárt O, Győrffy B. Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches[J]. Cancer Metastasis Rev, 2020, 39(11): 211-233. doi: 10.1007/s10555-020-09854-1
 | 
																													
																							| [19] | Perreault S, Ramaswamy V, Achrol AS,  et al. MRI surrogates for molecular subgroups of medulloblastoma[J]. AJNR Am J Neuroradiol, 2014, 35(7): 1263-1269. doi: 10.3174/ajnr.A3990
 | 
																													
																							| [20] | Taylor MD, Northcott PA, Korshunov A,  et al. Molecular subgroups of medulloblastoma: the current consensus[J]. Acta Neuropathol, 2012, 123(4): 465-472. doi: 10.1007/s00401-011-0922-z
																																					pmid: 22134537
 | 
																													
																							| [21] | Rutkowski S, Bode U, Deinlein F,  et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone[J]. N Engl J Med, 2005, 352(10): 978-986. doi: 10.1056/NEJMoa042176
 | 
																													
																							| [22] | Geyer JR, Sposto R, Jennings M,  et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group[J]. J Clin Oncol, 2005, 23(30): 7621-7631. pmid: 16234523
 | 
																													
																							| [23] | Guerrini-Rousseau L, Dufour C, Varlet P,  et al. Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis[J]. Neuro Oncol, 2018, 20(8): 1122-1132. doi: 10.1093/neuonc/nox228
 | 
																													
																							| [24] | Menyhárt O, Győrffy B. Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches[J]. Cancer Metastasis Rev, 2020, 39(1): 211-233. doi: 10.1007/s10555-020-09854-1
 |